Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
ConditionAtrial Fibrillation (AF)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRegeneron Pharmaceuticals
About this trial
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation.
The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots.
The study is looking at several other research questions, including:
* What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Eligibility criteria
Qualifiers
Has AF or flutter (paroxysmal or persistent), not felt to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Thromboembolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve or
CHA2DS2-VA score ≥3 or
CHA2DS2-VA score of 2 and at least 1 enrichment criteria as described in the protocol
Disqualifiers
Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
Has known moderate-to-severe mitral stenosis
Has had successful ablation therapy or Left Atrial Appendage (LAA) occlusion/exclusion, or planned ablation or LAA occlusion/exclusion as described in the protocol
Had an ischemic stroke within 2 days prior to randomization
Trial design
Treatments tested in this trial
- REGN7508
- REGN9933
- Apixaban
Treatment groups
1,200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov